Share
.webp)
.webp)
.webp)
.webp)
Edna Venneker
Medincell, a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, has appointed Edna Venneker, MD, as Chief Medical Officer.
Venneker brings extensive international experience in drug development, with expertise spanning non-clinical and clinical strategy, regulatory affairs, program execution, and portfolio leadership. Her background includes broad experience across therapeutic areas and drug modalities, with particular expertise in neuroscience and central nervous system (CNS) disorders.
Most recently, Venneker served as Head of Development and Senior Vice President at Grünenthal, where she oversaw clinical development, clinical operations, chemistry, manufacturing and controls (CMC), and data science, including pharmacometrics and advanced analytics. She also served as Deputy Chief Medical Officer and was a member of the company’s R&D Leadership Team and R&D Portfolio Board.
Throughout her career, Venneker has led global, cross-functional development programs and supported strategic decision-making across the drug development lifecycle. She has also advised biotechnology and pharmaceutical companies on development and regulatory strategies, drawing on extensive experience working across international markets.
Her regulatory expertise includes direct interactions with major health authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
Venneker’s experience encompasses a broad range of product types, including small molecules, biologics, vaccines, and advanced therapies. Her combination of clinical development, regulatory, operational, and portfolio leadership experience will support Medincell as it advances its pipeline of long-acting injectable treatments.
In her new role, Venneker will contribute to Medincell’s clinical and development strategy and support the company’s efforts to advance innovative long-acting therapies across multiple therapeutic areas.
.webp "TransCode Therapeutics Appoints Jack E. Stover to Board of Directors")
